ACADIA Pharmaceuticals In...

AI Score

0

Unlock

16.89
-1.01 (-5.64%)
At close: Jan 14, 2025, 3:59 PM
16.90
0.03%
After-hours Jan 14, 2025, 07:30 PM EST
undefined%
Bid 16.62
Market Cap 2.81B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.78
PE Ratio (ttm) 21.66
Forward PE n/a
Analyst Buy
Ask 16.9
Volume 2,046,131
Avg. Volume (20D) 2,324,506
Open 18.15
Previous Close 17.90
Day's Range 16.61 - 18.23
52-Week Range 14.15 - 29.29
Beta undefined

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych...

Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2004
Employees 620
Stock Exchange NASDAQ
Ticker Symbol ACAD

Analyst Forecast

According to 18 analyst ratings, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $24, which is an increase of 42.05% from the latest price.

Buy 61.11%
Hold 33.33%
Sell 0.00%
Stock Forecasts

Next Earnings Release

ACADIA Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $282.92M, reflecting a 22.45% YoY growth and earnings per share of 0.23, making a -17.86% decrease YoY.
2 months ago · Source
+8.93%
ACADIA Pharmaceuticals shares are trading higher t... Unlock content with Pro Subscription
3 months ago · Source
-2.76%
ACADIA Pharmaceuticals shares are trading lower after the company appointed Catherine Owen Adams as CEO.